Pfizer Inc. with ticker code (PFE) now have 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $45.00 and $27.00 suggesting an average analyst share price target price of $32.88. (at the time of writing). Now with the previous closing price of $26.72 and the analysts are correct then there would likely be a percentage uptick in value of 23.1%. The 50 day moving average now sits at $28.71 and the 200 day moving average is $28.16. The total market capitalization for the company now stands at 147.46B. The price for the stock stands currently at: $26.02 USD
The potential market cap would be $181,430,013,802 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 34.69, revenue per share of $10.49 and a 3.31% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
